Several studies have been shown that up-regulation of ANRIL is regarded as a risk factor in several types of human cancers, including gastric, cancer, lung cancer, breast cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma etc. (Zhang et al., 2014[48]; Chen et al., 2015[7]; Lin et al., 2015[28]; Nie et al., 2015[35]). Here, CDKN2B-AS1 is linked to lung cancer.